Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting.Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
Overall, patients taking ASIs lived about 27 months, compared with 17 months for those who were not taking an ASI. In addition, patients taking ASIs were more likely to have the cancer shrink. Researchers also compared ASIs to other types of medications for high blood pressure, finding that patients taking other types of medications for high blood pressure lived about 18 months. Researchers also found that patients taking a type of cancer treatment known as VEGF therapy had a greater benefit when ASIs were combined with cancer treatment. VEGF therapy, such as sunitinib, sorafenib, axitinib, and bevacizumab also affects the process of angiogenesis, which may mean that an ASI works along with the VEGF therapy to better block the formation of blood vessels that feed cancer growth.
A new type of targeted immunotherapy (called MPDL3280A) was able to shrink several different types of cancer, including lung, melanoma, kidney, colorectal, and stomach cancers in patients whose cancer had worsened while receiving other treatments. Immunotherapy is designed to boost the body’s natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. Specifically, this new treatment targets PD-L1, a protein on the surface of tumor cells that prevents the immune system from fighting the tumor. Basically, this treatment stops PD-L1 from working, which then allows the body’s immune system to fight the cancer.
A recent analysis of information from the Surveillance Epidemiology and End Results (SEER) database showed that patients who had surgery to remove small kidney tumors (tumors that are less than 1.5 inches across) have the same risk of dying of kidney cancer over a five-year period as those who received surveillance instead. Surveillance of kidney cancer involves using imaging tests, such as magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT or CAT) scans to watch for signs that the cancer is growing or worsening.
A new immunotherapy (called BMS-936558) helped shrink melanoma, kidney cancer, and non-small cell lung cancer (NSCLC) in a recent early study. Immunotherapy is designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to bolster, target, or restore immune system function.
A recent study showed that patients with metastatic kidney cancer (kidney cancer that has spread to other parts of the body) preferred pazopanib (Votrient) to sunitinib (Sutent), reporting that they had better quality of life while receiving pazopanib. These drugs are a type of treatment called targeted therapy, which targets the cancer's specific genes, proteins, or tissue environment that contributes to cancer growth and survival. To help control cancer growth, patients with metastatic kidney cancer often need to take one of these drugs for many months or years. This means that they are also likely to experience side effects for as long as they take the drug, which can greatly affect their long-term quality of life.